Skip to content

Neuroplasticity: all studies

Page 130 of 178: studies 1,291 to 1,300 of 1,773, newest first. Back to the neuroplasticity overview

Research

Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

Frontiers in Pharmacology August 22, 2023 Mary G. Hornick, Ashley Stefanski 9 citations

The United States is entering its fourth decade of the opioid epidemic with no clear end in sight. At the center of the epidemic is an increase in opioid use disorder (OUD), a complex condition encompassing physical addiction, psychological comorbidities, and socioeconomic and legal travails associated with the misuse and abuse of opioids. Existing behavioral and medication-assisted therapies...

New Frontiers in Ketamine Research: From Mechanisms of Action to Novel Psychiatric Treatment Approaches

American Journal of Psychiatry and Neuroscience August 17, 2023 Marcus C. Rosenhagen, Julien Elowe, Alberto Forte et al.

Ketamine, initially developed as a safer alternative to phencyclidine, has emerged as a groundbreaking treatment in psychiatric practice. It gained popularity after its approval by the FDA in 1970 for its analgesic properties and ability to induce altered consciousness while maintaining vital functions. In the 1990s, researchers discovered its rapid and potent antidepressant effects, especially...

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report

August 16, 2023 Kevin Rebecchi 2 citations preprint

This retrospective case report explores the impact of psilocybin mushroom intake on the emergence of mental imagery in an autistic woman with aphantasia. Aphantasia refers to the inability to generate visual mental images, which can significantly affect individuals' experiences and cognitive processes. The case study focuses on a 34-year-old autistic woman who had been living with aphantasia...

Ketamine: A new chapter for clinical psychopharmacology?

Journal of Psychopharmacology August 1, 2023 A. H. Young

Ketamine is an N-methyl-D-aspartate antagonist which has been a major focus of research recently and is being used as a putative treatment for depression and other neuropsychiatric disorders. Along with psychedelic agents, ketamine (and the derivative esketamine) are not only the main harbingers of potentially new classes of psychiatric drugs but may also share some common features (Marguilho...

Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression.

Journal of Psychopharmacology August 2023 Matthew Burrows, Vasileia Kotoula, Ottavia Dipasquale et al.

Resting state connectivity studies link ketamine's antidepressant effects with normalisation of the brain connectivity changes that are observed in depression. These changes, however, usually co-occur with improvement in depressive symptoms, making it difficult to attribute these changes to ketamine's effects per se. Our aim is to examine the effects of ketamine in brain connectivity, 2 h after...

SAINDO DO ESTIGMA: PSICODÉLICOS COMO ALTERNATIVA VIÁVEL NA PROMOÇÃO DA SAÚDE MENTAL

August 1, 2023 Gabriel Alexandre Moura, ANA Cecilia de Carvalho Cunha, Beatriz Barros Cordeiro et al.

Objetivo: O uso de psicodélicos em psicoterapia tem sido objeto de interesse crescente na última década.Portanto, o objetivo desta revisão sistemática é examinar a literatura científica mais recente sobre os benefícios do uso de psicodélicos na promoção da saúde mental.Metodologia: Os descritores para essa pesquisa foram selecionados pela Descritores em ciência da saúde (DeCS/MeSH), da...

CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity.

Frontiers in Pharmacology July 31, 2023 Valentina Castelli, Gianluca Lavanco, Cesare D'Amico et al.

Introduction: An altered neurodevelopmental trajectory associated with prenatal exposure to ∆-9-tetrahydrocannabinol (THC) leads to aberrant cognitive processing through a perturbation in the effectors of hippocampal plasticity in the juvenile offspring. As adolescence presents a unique window of opportunity for "brain reprogramming", we aimed at assessing the role of the non-psychoactive...

Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression

Pharmacopsychiatry July 30, 2023 Kengo Yonezawa, Hiroyuki Uchida, Taisuke Yatomi et al. 8 citations

Abstract Introduction Predictors of treatment response to intravenous ketamine remain unclear in patients with treatment-resistant depression (TRD); therefore, this study aimed to clarify these predictors using the US National Institutes of Health database of clinical trials. Methods Data from a placebo-controlled, double-blind, randomized controlled trial were used to assess the efficacy of...

All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegener-ative diseases through mitochondrial activation

Science Reviews Biology July 30, 2023 Milena Batalla 2 citations

The sigma-1 receptor S1R is a chaperone that resides mainly at the mitochondrion-associated endoplasmic reticulum ER membrane MAM, it is considered a “pluripotent modulator” in living systems, plays a critical role in maintaining neuronal homeostasis and acts as a dynamic pluripotent modulator in living systems. Given its specific localization at the MAM, S1R plays a major role regulating...

DOI: 10.57098/scirevs.biology.2.2.1 (opens in new tab) Sigma-1 receptor Epigenetics Mitochondrion Agonist +2

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

Neuropsychopharmacology July 24, 2023 John H. Krystal, Ege T Kavalali, Lisa M Monteggia 229 citations

Ketamine is an open channel blocker of ionotropic glutamatergic N -Methyl- D -Aspartate (NMDA) receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression fostered novel effective treatments for mood disorders. This discovery not only provided new insight into the neurobiology of mood disorders but also uncovered fundamental...